TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Government & Organizations

    Psychopharmacology and Psychiatry Updates

    Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

    Advertise
    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Second-Generation Antipsychotics for OCD Augmentation Oct 23, 2026
    Show notes

    Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation
    • Second-Generation Antipsychotics for OCD Augmentation: Third-Line Agents
    Are Z-Drugs Safe in the First Trimester of Pregnancy? Oct 18, 2026
    Show notes

    In this episode, we review a JAMA Psychiatry study of over 4 million pregnancies examining first-trimester Z-drug exposure and congenital malformations. Dr. Amanda Koire explains why overall risk wasn't increased, what the neural tube defect signal means, and how to evaluate insomnia before prescribing.

    Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D.

    • Learn more about our membership here
    • Earn 0.75 CMEs: Quick Take Vol. 86
    • Are Z-Drugs Safe in the First Trimester of Pregnancy?
    Glutamatergic Augmentation in OCD Oct 13, 2026
    Show notes

    Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation
    • Glutamatergic Augmentation in OCD: Memantine, Riluzole, Lamotrigine and Other Agents
    Schizophrenia: Which of Seven Antipsychotics Wins? Oct 09, 2026
    Show notes

    Faculty: Oliver Freudenreich, M.D. Host: Flavio Guzmán, M.D.

    • Learn more about our memberships here
    • Earn 0.75 CMEs: Quick Take Vol. 85
    • Schizophrenia: Which of Seven Antipsychotics Wins on Acute Efficacy and Safety?
    SSRI Dosing for OCD: Beyond FDA Guidelines Oct 03, 2026
    Show notes

    Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: SSRI Dosing for OCD: Beyond FDA Guidelines
    • Treatment-Resistant OCD: From SSRIs to Augmentation
    Trazodone for Insomnia and Comorbid Depression Sep 28, 2026
    Show notes

    In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, examining its effects on sleep architecture and depressive symptoms in patients with comorbid insomnia and depression, alongside its notable side effect profile. Can a decades-old antidepressant be the missing link for restorative sleep?

    Faculty: Paul Zarkowski, M.D. Host: Flavio Guzmán, M.D.

    • Learn more about our memberships here
    • Earn 0.5 CMEs: Quick Take Vol. 85
    • Trazodone for Insomnia and Comorbid Depression: Are the AASM Guidelines Relevant?
    Antipsychotics, Prolactin, and Sexual Side Effects Sep 23, 2026
    Show notes

    In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the highest risk, the long-term health implications, and practical strategies for monitoring, switching, or augmenting therapy.

    Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know
    • Managing Hyperprolactinemia and Sexual Side Effects from Antipsychotic Use
    EMERGENT-5: Cobenfy and Treatment Durability Sep 18, 2026
    Show notes

    In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist.

    Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

    • Learn more about our membership here
    • Earn 0.5 CME: Quick Take Vol. 85
    • Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?
    Antipsychotics and Weight Gain Sep 13, 2026
    Show notes

    In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health.

    Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know
    • Antipsychotic-Induced Weight Gain: Prevention and Management
    EPA vs. DHA: Fish Oil and Treatment-Resistant Depression Sep 08, 2026
    Show notes

    In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms.

    Faculty: Derick E. Vergne, M.D. Host: Richard Seeber, M.D.

    • Learn more about our memberships here
    • Earn 0.75 CMEs: Quick Take Vol. 84
    • Eicosapentaenoic Acid: Effective as Adjunctive for TRD?
    1 2 3 11 Next

    Related Podcasts

    The Joe Rogan Experience

    1

    The Joe Rogan Experience Comedy
    More Perfect

    2

    More Perfect Government
    Casefile True Crime

    3

    Casefile True Crime Games & Hobbies
    Reply All

    4

    Reply All Games & Hobbies
    You Must Remember This

    5

    You Must Remember This Games & Hobbies
    Real Time with Bill Maher

    6

    Real Time with Bill Maher Games & Hobbies
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights